Caplyta (generic name: lumateperone) is a prescription medication used to treat schizophrenia in adults. It belongs to a class of drugs called atypical antipsychotics, which work by altering the activity of certain chemicals in the brain. CAPLYTA exhibits moderate affinity for the dopamine D1 receptor.1 The binding of CAPLYTA to the dopamine D1 receptor may contribute to indirect activation of the glutamatergic AMPA and NMDA receptors.3 The clinical relevance of CAPLYTA receptor-binding affinities is unknown.1 In short caplyta is a 2nd generation atypical antipsychotic medication that was originally tested for schizophrenia and bi polar disorder. The medication works on the dopamine receptor which is strongly believed to be the cause of certain childhood onset fluency disorders.